Search…

Hengrui Medicine (01276): HRS-2189 Tablets Approved to Initiate Clinical Trials

28/10/2026

Zhitong Finance APP News, Hengrui Pharmaceuticals (01276) announced that recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HRS-2189 tablets, and will soon initiate clinical trials.

Latest

4 m ago

Gosuncn (300098.SZ) released its first three quarters results, with net profit attributable to shareholders of RMB 41.179 million, down 35.21% year on year.

4 m ago

Jinlong Machinery & Electronics (300032.SZ) released its first three quarters performance, with a net loss attributable to shareholders of RMB 49.4681 million.

5 m ago

Seagull Kitchen and Bath Products (002084.SZ) released its first three quarters performance, with a net loss attributable to shareholders of RMB 52.0029 million.

6 m ago

Junshi Biosciences (01877.HK): Toripalimab Receives Regular Approval from the National Medical Products Administration for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma That Has Failed Platinum-Containing Chemotherapy

10 m ago

Hubei Yihua (000422.SZ) released its first three quarters results, with net profit attributable to the parent company of 327 million yuan, a year-on-year decrease of 59.69%.

See all latest